Literature DB >> 18077611

A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax.

Larry I Gilderman1, James F Lawless, Thomas M Nolen, Tina Sterling, Ruth Z Rutledge, Doreen A Fernsler, Neal Azrolan, Santosh C Sutradhar, William W Wang, Ivan S F Chan, Katia Schlienger, Florian Schödel, Jeffrey L Silber.   

Abstract

The vaccine Zostavax has been shown to prevent herpes zoster (HZ) and postherpetic neuralgia and is recommended for individuals > or =60 years of age. This study compared the safety and the immunogenicity of a refrigerator-stable formulation (Zostavax refrigerated) with those of the current formulation (Zostavax frozen) in subjects > or =50 years of age. Subjects with a negative history for HZ were randomized 1:1 to receive one dose of either formulation. Enrollment was stratified 1:2 by age (50 to 59 years and > or =60 years). Safety was evaluated for 28 days postvaccination. Varicella-zoster virus (VZV) antibody responses were measured by a glycoprotein enzyme-linked immunosorbent assay (gpELISA). The primary endpoints were the VZV antibody geometric mean titer (GMT; day 28), the VZV antibody geometric mean rise (GMR; days 1 to 28), and the incidence of vaccine-related serious adverse experiences (AEs) over 28 days. The refrigerated (n = 182) and frozen (n = 185) formulations induced similar GMTs (727.4 and 834.4 gpELISA units/ml, respectively); the estimated GMT ratio (refrigerated formulation/frozen formulation) was 0.87 (95% confidence interval, 0.71 to 1.07). The GMRs were 2.6- and 2.9-fold, respectively. No vaccine-related serious AEs were reported in either group, and the safety profiles of the formulations were generally similar. The frequencies of injection-site AEs during follow-up were 35.6% and 46.4% in the refrigerated and the frozen formulation groups, respectively, and were generally mild. The frequencies of systemic AEs were similar in the two groups, and those of vaccine-related AEs were approximately 6% in both groups. The refrigerator-stable formulation of Zostavax has an acceptable safety profile and is as immunogenic as the frozen formulation; thus, the vaccine may be used in clinical settings where freezer availability is limited.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18077611      PMCID: PMC2238040          DOI: 10.1128/CVI.00310-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  34 in total

Review 1.  Postherpetic neuralgia.

Authors:  C P Watson
Journal:  Contrib Microbiol       Date:  1999

Review 2.  Herpes zoster: focus on treatment in older adults.

Authors:  R J Whitley; J W Gnann
Journal:  Antiviral Res       Date:  1999-12-31       Impact factor: 5.970

3.  An analysis of clinical risks in vaccine transportation.

Authors:  Martina Fernando
Journal:  Br J Community Nurs       Date:  2004-10

4.  Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects > or =13 years of age.

Authors:  Clemente Diaz; Pietro Dentico; Rocio Gonzalez; Rafael G Mendez; Sandro Cinquetti; Julie L Barben; Anna Harmon; Ira Chalikonda; Jeffrey G Smith; Jon E Stek; Andrew Robertson; Michael J Caulfield; Luigi R Biasio; Jeffrey L Silber; Christina Y Chan; Rupert Vessey; Jerald Sadoff; Ivan S F Chan; Holly Matthews; William Wang; Katia Schlienger; Florian P Schödel
Journal:  Vaccine       Date:  2006-07-07       Impact factor: 3.641

5.  Varicella zoster vaccine (Varivax).

Authors:  E A Farrington
Journal:  Pediatr Nurs       Date:  1995 Jul-Aug

Review 6.  Early treatment of herpes zoster.

Authors:  S K Tyring
Journal:  Hosp Pract (1995)       Date:  1996-07-15

7.  Postherpetic neuralgia. Predicting and preventing risk.

Authors:  R G Kost; S E Straus
Journal:  Arch Intern Med       Date:  1997-06-09

Review 8.  Herpes zoster in older adults.

Authors:  K Schmader
Journal:  Clin Infect Dis       Date:  2001-04-17       Impact factor: 9.079

9.  Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.

Authors:  Boris Kerzner; Alexander V Murray; Eric Cheng; Rudy Ifle; Peter R Harvey; Mark Tomlinson; Julie L Barben; Kimberly Rarrick; Jon E Stek; Mi-Ok Chung; Florian P Schödel; William W B Wang; Jin Xu; Ivan S F Chan; Jeffrey L Silber; Katia Schlienger
Journal:  J Am Geriatr Soc       Date:  2007-10       Impact factor: 5.562

10.  Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live).

Authors:  Henry H Bernstein; Karen Eves; Kristy Campbell; Steven B Black; Jerry D Twiggs; Keith S Reisinger; Ralph M Conti; Carl-Erik Flodmark; Lars Rombo; Stephanie Klopfer; Florian Schödel; Jonathan Hartzel; Barbara J Kuter
Journal:  Pediatrics       Date:  2007-05-14       Impact factor: 7.124

View more
  23 in total

1.  Immune response to a refrigerator-stable zoster vaccine.

Authors:  Myron J Levin; Michael N Oxman; Gary R Johnson; Jane H Zhang; Anthony R Hayward; Adriana Weinberg
Journal:  Clin Vaccine Immunol       Date:  2009-09

Review 2.  Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.

Authors:  Kristine Macartney; Anita Heywood; Peter McIntyre
Journal:  Cochrane Database Syst Rev       Date:  2014-06-23

3.  Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.

Authors:  Timo Vesikari; Roland Hardt; Hans C Rümke; Giancarlo Icardi; Jordi Montero; Stéphane Thomas; Christine Sadorge; Anne Fiquet
Journal:  Hum Vaccin Immunother       Date:  2013-01-14       Impact factor: 3.452

4.  Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years.

Authors:  Robert Arnou; Anne Fiquet; Stéphane Thomas; Christine Sadorge
Journal:  Hum Vaccin       Date:  2011-10-01

Review 5.  Vaccination in the elderly: what can be recommended?

Authors:  Pierre-Olivier Lang; Richard Aspinall
Journal:  Drugs Aging       Date:  2014-08       Impact factor: 3.923

Review 6.  Herpes zoster vaccine live: A 10 year review of post-marketing safety experience.

Authors:  English D Willis; Meredith Woodward; Elizabeth Brown; Zoran Popmihajlov; Patricia Saddier; Paula W Annunziato; Neal A Halsey; Anne A Gershon
Journal:  Vaccine       Date:  2017-11-22       Impact factor: 3.641

7.  STATEMENT ON THE RECOMMENDED USE OF HERPES ZOSTER VACCINE: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)*.

Authors:  Kevin Laupland
Journal:  Can Commun Dis Rep       Date:  2010-01-25

8.  Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

Authors:  Kenneth E Schmader; Myron J Levin; John W Gnann; Shelly A McNeil; Timo Vesikari; Robert F Betts; Susan Keay; Jon E Stek; Nickoya D Bundick; Shu-Chih Su; Yanli Zhao; Xiaoming Li; Ivan S F Chan; Paula W Annunziato; Janie Parrino
Journal:  Clin Infect Dis       Date:  2012-01-30       Impact factor: 9.079

9.  A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK.

Authors:  Lee Moore; Vanessa Remy; Monique Martin; Maud Beillat; Alistair McGuire
Journal:  Cost Eff Resour Alloc       Date:  2010-04-30

10.  Immune Responses to Varicella-Zoster Virus Glycoprotein E Formulated with Poly(Lactic-co-Glycolic Acid) Nanoparticles and Nucleic Acid Adjuvants in Mice.

Authors:  Yunfei Wang; Jialong Qi; Han Cao; Cunbao Liu
Journal:  Virol Sin       Date:  2020-08-05       Impact factor: 4.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.